| 吉非替尼联合紫龙金片治疗中晚期非小细胞肺癌的临床观察 |
| |
| 引用本文： | 房芳,陈红,庞红梅,宋文广,王瑞林,王海波.吉非替尼联合紫龙金片治疗中晚期非小细胞肺癌的临床观察[J].现代预防医学,2011,38(7):1346-1348. |
| |
| 作者姓名： | 房芳 陈红 庞红梅 宋文广 王瑞林 王海波 |
| |
| 作者单位： | 1. 唐山市工人医院肿瘤科,唐山,063000
2. 唐山工人医院分院消化科 |
| |
| 摘 要： | 目的]观察吉非替尼(gefitinb,易瑞沙,Iressa)联合紫龙金片治疗中晚期非小细胞肺癌(NSCLC)的临床疗效和不良反应。方法]将患者分为联合组(36)例和单药组(35)例,两组均自服吉非替尼250mg1次/d,联合组加服紫龙金片2.6g3/日。治疗60d后评价近期疗效、观察不良反应,随访2年评价客观疗效和生存率。结果]联合组有效率(27.8%);单药组CR有效率(20.0%),差异无统计学意义(P﹥0.05)。联合组疾病控制率高于单药组,但在统计学上未见显著差异;联合组症状改善率88.9%(32/36)高于单药组68.6%(24/35),两组相比较差异有统计学意义(P﹤0.05);联合组皮疹、腹泻、恶心呕吐、肝功能异常等不良反应发生率低于单药组,相比较差异无统计学意义(P﹥0.05)。结论]吉非替尼联合紫龙金片治疗NSCLC效果优于单用吉非替尼治疗的效果,并使患者的生活质量得到了进一步的改善,值得临床上进一步推广应用。
|
| 关 键 词： | 非小细胞肺癌 吉非替尼 紫龙金片 分子靶向治疗 |
CLINICAL OBSERVATION OF GEFITINIB COMBINED WHIH ZILONGJIN TABLETS IN TREATMENT OF ADVANCED NON-SMALL-CELL LUNG CANCER |
| |
| FANG Fang,CHEN Hong,PANG Hong-mei,et al..CLINICAL OBSERVATION OF GEFITINIB COMBINED WHIH ZILONGJIN TABLETS IN TREATMENT OF ADVANCED NON-SMALL-CELL LUNG CANCER[J].Modern Preventive Medicine,2011,38(7):1346-1348. |
| |
| Authors: | FANG Fang CHEN Hong PANG Hong-mei |
| |
| Institution: | FANG Fang,CHEN Hong,PANG Hong-mei,et al.(Department of Oncology,Tangshan Workers Hospital,Tangshan 063000,China) |
| |
| Abstract: | Objective]To evaluate the clinical efficacy and side effect of gefitinib and Zilongjin tables in advanced non-small-cell lung cancer(NSCLC).Methods]71cases of NSCLC were divided into combination group(36 cases)and single drug group(35 cases).The combination group was given the treatment of gefitinib 250mg/d and Zilongjin tablets 2.6g 3/d,the single drug group was given the treatment of gefitinib alone.After treated for 60 days,the short-term efficacy and toxicity were evaluated,followed up lasted for 2-ye... |
| |
| Keywords: | Non-small-cell lung cancer Gefitinib Zilongjin tables Molecular target therapy |
| 本文献已被 CNKI 万方数据 等数据库收录！ |
|
